Novartis | NVS - Interest Expense On Debt



Novartis reported $289M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Amgen USD 694M 29M Jun/2025
AstraZeneca 303M 126M Jun/2025
Bausch Health Companies USD 465M 135M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Canopy Growth CAD 9.74M 7.03M Jun/2025
Corcept Therapeutics 6M 6M Jun/2024
Drreddys Laboratories INR 817M 60M Dec/2024
Eli Lilly USD 249M 5.3M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Glaxosmithkline 184M 5.95M Jun/2025
J&J USD 128M 9M Mar/2025
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Novartis USD 289M 14M Jun/2025
Pacira USD 3.82M 110K Jun/2025
Perrigo 39.6M 600K Jun/2025
Pfizer USD 654M 0 Jun/2025
Prestige Brands USD 10.2M 275K Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sanofi 148M 65M Jun/2025
Sanofi 62M 4.11M Jun/2025
Supernus Pharmaceuticals USD 0 0 Dec/2024
Zoetis USD 53M 1000K Jun/2025